Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Silexion Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Silexion Therapeutics's regulatory disclosures and financial reporting.
Silexion Therapeutics reported early laboratory findings suggesting its lead RNAi candidate SIL204 may have an immune-modulating effect in KRAS-driven cancers. In a preclinical study using human pancreatic cancer cells with a KRAS G12R mutation, SIL204 treatment led to a statistically significant increase in MHC-I (HLA-ABC) expression, a key signal that helps cytotoxic T cells recognize tumor cells. The company notes this could support future evaluation of SIL204 in combination with anti-PD-1 immunotherapies such as pembrolizumab, although these results remain preliminary and preclinical. Silexion is advancing SIL204 towards clinical trials in Israel and the European Union for locally advanced pancreatic cancer.
Silexion Therapeutics Corp is advancing its lead RNAi cancer drug SIL204 by starting Good Manufacturing Practice (GMP) clinical batch manufacturing with Catalent at its Limoges, France facility. These clinical batches will be used as investigational medicinal product for the safety run-in segment of a planned Phase 2/3 trial in locally advanced pancreatic cancer.
The company also received approval from the Helsinki Ethics Committee of Tel Aviv Sourasky Medical Center for the planned Phase 2/3 study at this leading Israeli oncology site, following prior authorization from the Israeli Ministry of Health and a Clinical Trial Application submission in Germany. Together, the manufacturing progress and multi-country regulatory steps move SIL204 closer to first patient dosing in a Phase 2/3 trial combining SIL204 with standard chemotherapy and using a dual-route (intratumoral and systemic) administration strategy.
Silexion Therapeutics Corp held a reconvened extraordinary general meeting on May 5, 2026, where shareholders approved several capital structure changes. The key step was a Memorandum Amendment increasing authorized share capital from US$121,500, divided into 9,000,000 ordinary shares, to US$796,500, divided into 59,000,000 ordinary shares, each with a par value of US$0.0135. Shareholders also approved an evergreen increase and a reverse share split proposal. The meeting proceeded after 1,638,079 ordinary shares, representing about 40.2% of issued and outstanding shares, constituted a quorum under the company’s articles. Each proposal received around 61% of votes cast in favor, meeting the simple majority threshold.
Silexion Therapeutics Corp furnished an update that it has successfully submitted a Clinical Trial Application in Germany for a planned Phase 2/3 trial of its lead siRNA therapy, SIL204, in KRAS-driven locally advanced pancreatic cancer. Germany will act as the Reporting Member State for the European Union review under the CTIS system, following earlier approval from the Israeli Ministry of Health for the same Phase 2/3 trial. The company plans to start the global Phase 2/3 study in the second quarter of 2026, combining intratumoral and systemic administration of SIL204 with standard chemotherapy at leading oncology centers in Germany, other EU states and Israel.
Silexion Therapeutics Corp is asking shareholders to approve three major capital-structure changes at an extraordinary general meeting on April 28, 2026. The board wants to increase authorized share capital from 9,000,000 to 59,000,000 ordinary shares, citing a lack of unissued shares and the need to maintain at least $2.5 million of shareholders’ equity required by Nasdaq.
A second proposal would amend the 2024 Equity Incentive Plan’s evergreen provision so that, each January 1, the pool reserved under all equity plans equals 10% of issued and outstanding shares on a fully diluted basis, up from a 5% of outstanding-shares formula. The third proposal authorizes a reverse share split of all ordinary shares, at a ratio between 1‑for‑4 and 1‑for‑10, to help keep the Nasdaq bid price above $1.00 and avoid potential delisting, without changing each holder’s percentage ownership aside from minor rounding of fractional shares.
Silexion Therapeutics Corp CSO and CDO Shirvan Mitchell reported an open-market sale of 22,818 Ordinary Shares on March 26, 2026 at $1.36 per share. According to the footnotes, this was a sale-to-cover transaction to pay tax liabilities from a fully vested restricted share unit grant received on February 20, 2026.
After the sale, Mitchell directly held 27,889 Ordinary Shares. He also held a stock option over 478 Ordinary Shares with an exercise price of $907.71 per share and an expiration date of June 7, 2032, adjusted to reflect prior reverse share splits.
Silexion Therapeutics Corp files its annual report as a clinical‑stage biotech focused on RNA‑interference therapies for KRAS‑driven cancers, initially pancreatic cancer. Its lead candidate, SIL204, is an optimized siRNA designed to silence mutated KRAS and be used with standard chemotherapy.
The company plans an adaptive Phase 2/3 trial in locally advanced pancreatic cancer starting in the second quarter of 2026, with about 403 patients overall and an initial 15–21‑patient safety run‑in. Prior Phase 2 data with its first‑generation siRNA showed a non‑significant trend toward longer overall survival when added to chemotherapy.
Silexion discloses heavy reliance on external manufacturers, the need to raise substantial additional funding (including via an at‑the‑market program and warrant exercises), potential dilution from converting sponsor notes, and risks tied to operations in Israel and maintaining its Nasdaq listing. As of March 10, 2026, 3,330,785 ordinary shares were outstanding.
Noy Shlomo reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that Guangzhou Sino-Israel Biotech Fund (GIBF), an entity associated with director Noy Shlomo, was granted equity awards in connection with director services provided by GIBF’s CEO and Managing Partner, Avner Lushi. GIBF received fully vested restricted share units that were immediately settled into 9,091 ordinary shares, at a price of $0.00 per share. GIBF was also granted 10,685 stock options to purchase ordinary shares, with these options vesting in full on the one‑year anniversary of the board’s approval date and expiring on the ten‑year anniversary of that approval. The filing notes that Shlomo has shared voting and investment authority through his role as Chief Medical Officer of GIBF and disclaims beneficial ownership beyond any indirect pecuniary interest, and one line item is included only to show existing holdings with no new transaction.
Silexion Therapeutics Corp director Alon Ruth received new equity awards in the form of both shares and options. On February 20, 2026, Ruth was granted 9,091 Ordinary Shares at a price of $0.0000 per share, issued through fully vested restricted share units that were immediately settled into ordinary shares for his board service.
On the same date, he also received a grant of stock options covering 10,685 Ordinary Shares at an exercise price of $0.0000 per share, reflecting compensation for his role as a director. According to the filing, these options vest in full on the one-year anniversary of the grant approval date and expire on the ten-year anniversary of that approval date, providing a long-dated incentive tied to his continued board service. An additional row in the filing simply updates existing option holdings and does not reflect a new transaction.
Shirvan Mitchell reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp chief scientific and development officer Shirvan Mitchell received a grant of 49,726 fully vested restricted share units that were immediately settled into ordinary shares at no cost, for his services as an officer and approved by the board. Following this award, his direct holdings total 50,707 ordinary shares, and he also directly holds stock options covering 478 ordinary shares, which are reported here for informational purposes only. The share and option amounts reflect prior 1-for-9 and 1-for-15 reverse share splits effective in late 2024 and mid‑2025.